Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,361 across all filing types
Latest filing 2024-04-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Audit Report" for the fiscal year ending December 31, 2023, issued by an accounting firm (Grant Thornton) to the shareholders of 亚宝药业集团股份有限公司. It discusses the audit of the effectiveness of internal controls over financial reporting, references auditing standards and responsibilities, and provides an audit opinion on internal control effectiveness. The document is 3801 characters long, which is relatively short and focused solely on the internal control audit. It is not a full annual report (10-K) or interim report (IR) because it does not contain comprehensive financial statements or detailed financial analysis. It is not a certification letter or a brief announcement but a standalone audit report on internal controls. Therefore, it fits the category of Audit Report / Information (AR).
2024-04-25 Chinese
亚宝药业集团股份有限公司2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 Annual Report Summary" of 亚宝药业集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2023, including total assets, net profit, revenue, and quarterly breakdowns. It also includes company business overview, industry context, shareholder information, and profit distribution plans. The presence of audited financial figures and comprehensive business and financial data confirms this is a full annual report document rather than a brief announcement or presentation. The document length (9591 characters) supports it being a substantive report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-25 Chinese
亚宝药业集团股份有限公司第九届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 9th Board of Directors 5th meeting of 亚宝药业集团股份有限公司. It includes approvals of the 2023 annual report, board work report, financial statements, profit distribution plan, appointment of auditors, internal control evaluation, social responsibility report, accounting estimate changes, and the 2024 Q1 report. It also mentions plans for capital reduction and shareholder dividend planning, and the calling of the 2023 annual general meeting. The document is a formal board meeting resolution announcement rather than the full annual report or financial statements themselves. It references other announcements and reports published elsewhere. The document length is 2337 characters, which is relatively short and consistent with a meeting resolution announcement. Therefore, this is best classified as a Board/Management Information (MANG) filing, as it announces board meeting decisions and management approvals rather than being the full report or a simple announcement of report publication.
2024-04-25 Chinese
亚宝药业集团股份有限公司2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and shareholder information for the first quarter of 2024. The report explicitly states it is unaudited and covers the period January to March 2024. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). Q1 2024
2024-04-25 Chinese
亚宝药业2023年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report' and is issued by a certified public accounting firm (致同会计师事务所). It contains detailed audit opinions, basis for audit opinions, key audit matters, and responsibilities of management and auditors. The document includes consolidated and company balance sheets, profit statements, cash flow statements, changes in shareholders' equity, and notes to the financial statements for the fiscal year ending December 31, 2023. The content is comprehensive and contains actual financial data and audit analysis, not just an announcement or summary. Therefore, this document fits the category of an Audit Report / Information (AR).
2024-04-25 Chinese
亚宝药业2023年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a standalone report on internal control evaluation, not a full annual report (10-K) or audit report in the traditional sense. The document length is 4474 characters, which is relatively short but contains substantive evaluation content. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on internal controls and their effectiveness, excluding a full annual report. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.